BYSI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	95 475.00
Średni wolumen	227 936
Kapitalizacja rynkowa	99.10M
EPS	$0 ( 2024-05-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.70
ATR14	$0.0520 (2.05%)

Wolumen Korelacja

Długi: 0.24 (neutral)

Krótki: 0.57 (weak)

Signal:(53.799) Neutral

BeyondSpring Inc Korelacja

10 Najbardziej pozytywne korelacje
INTZ	0.941
PRAX	0.936
QRTEA	0.932
AIHS	0.927
ERIE	0.924
RUBY	0.923
VVOS	0.922
VERU	0.921
JAGX	0.92
SOUN	0.919

10 Najbardziej negatywne korelacje
KNBE	-0.922
TIG	-0.912
SNCR	-0.906
SGEN	-0.896
XEL	-0.893
SABR	-0.892
ORTX	-0.889
DCRC	-0.888
CCRC	-0.884
XM	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BeyondSpring Inc Korelacja - Waluta/Towar

-0.31
( neutral )

-0.57
( weak negative )

0.00
( neutral )

-0.66
( moderate negative )

0.08
( neutral )

0.30
( neutral )

BeyondSpring Inc Finanse

Annual	2023
Przychody:	$1.75M
Zysk brutto:	$1.75M (100.00 %)
EPS:	$-0.540

FY	2023
Przychody:	$1.75M
Zysk brutto:	$1.75M (100.00 %)
EPS:	$-0.540

FY	2022
Przychody:	$1.35M
Zysk brutto:	$1.35M (100.00 %)
EPS:	$-0.930

FY	2021
Przychody:	$1.35M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.14

Financial Reports:

No articles found.

BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.